Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy
Status:
Recruiting
Trial end date:
2026-05-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn about the efficacy and safety of trastuzumab
emtansine (T-DM1) in the treatment of patients with advanced HER2-positive breast cancer
after TKIs or HP therapy. The main questions it aims to answer are:
- The objective response rate of patients receiving T-DM1 therapy with advanced
HER2-positive breast cancer after TKIs or HP therapy.
- The adverse events and prognosis of patients with advanced HER2-positive breast cancer
who receive the T-DM1 therapy.
- Changes of anti-tumor immunity during T-DM1 therapy in patients with advanced
HER2-positive breast cancer.
Participants will receive T-DM1 treatment (3.6mg/kg, d1/21, IVD) until progressive diseases
or intolerable adverse effects occurs.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University